 |
| |
| May-20-19 | Downgrade |
Argus |
Buy → Hold |
|
|
| May-03-19 | Upgrade |
Barclays |
Equal Weight → Overweight |
$53 → $55 |
|
| May-03-19 | Resumed |
JP Morgan |
Overweight |
$62 |
|
| Jan-15-19 | Upgrade |
Societe Generale |
Sell → Buy |
|
|
| Oct-22-18 | Downgrade |
Citigroup |
Buy → Neutral |
|
|
| Oct-09-18 | Resumed |
Guggenheim |
Neutral |
|
|
| Aug-08-18 | Upgrade |
Atlantic Equities |
Underweight → Neutral |
|
|
| Apr-17-18 | Downgrade |
Morgan Stanley |
Overweight → Equal-Weight |
|
|
| Apr-12-18 | Reiterated |
Citigroup |
Buy |
$78 → $70 |
|
| Mar-20-18 | Reiterated |
JP Morgan |
Overweight |
$70 → $75 |
|
| Feb-15-18 | Upgrade |
Morgan Stanley |
Equal-Weight → Overweight |
|
|
| Oct-30-17 | Upgrade |
SunTrust |
Hold → Buy |
|
|
| Oct-16-17 | Downgrade |
Jefferies |
Buy → Hold |
|
|
| Sep-12-17 | Downgrade |
Hilliard Lyons |
Long-term Buy → Neutral |
|
|
| Dec-19-16 | Upgrade |
Jefferies |
Hold → Buy |
|
|
| Oct-28-16 | Reiterated |
Deutsche Bank |
Hold |
$59 → $52 |
|
| Sep-09-16 | Reiterated |
Barclays |
Equal Weight |
$75 → $65 |
|
| Aug-11-16 | Downgrade |
Berenberg |
Buy → Hold |
|
|
| Aug-08-16 | Reiterated |
Deutsche Bank |
Hold |
$68 → $62 |
|
| Aug-08-16 | Downgrade |
Credit Suisse |
Outperform → Neutral |
$63 |
|
|
|
| May-24-19 06:59AM | Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes Business Wire |
| May-23-19 04:15PM | Synlogic (SYBX) Enters Cancer Collaboration with Roche Zacks |
| 03:46PM | Novartis Reports Data on Asthma Drug, Update from Annual Meet Zacks |
| May-22-19 05:13PM | Array BioPharma Gains on Colorectal Cancer Study Success Zacks |
| 03:42PM | Mallinckrodt (MNK) Down After Filing Suit Against HHS and CMS Zacks |
| 12:38PM | Merck's Keytruda Vs. Bristol-Myers Squibb's Opdivo In Q1 And Beyond Benzinga |
| 09:37AM | Merck to Buy Private Cancer Drugmaker Peloton Therapeutics Zacks |
| 07:00AM | Bristol-Myers Stock Continues to Slump, but Director Ted Samuels Is Buying Up Shares Barrons.com |
| May-21-19 08:13AM | Merck agrees $1bn deal to buy biopharmaceutical company Peloton Financial Times |
| May-20-19 06:32PM | 4 New Stock Picks From Seth Klarman GuruFocus.com |
| 02:28PM | Argus Questions Logic Behind Bristol-Myers' Proposed Celgene Buy, Steps To Sidelines Benzinga |
| 12:31PM | Drugmakers lobbying spending at 10-year high as Washington targets soaring prices MarketWatch |
| 09:16AM | Bristol-Myers Stock Is Falling Because the Celgene Merger May Not Make Sense Barrons.com |
| May-17-19 05:19PM | Roche Gets FDA Nod for Venclexta Plus Gazyva to Treat CLL Zacks |
| 05:17PM | Celgene Gets EC Nod for Label Expansion of Revlimid, Imnovid Zacks |
| May-16-19 04:15PM | Bristol-Myers Squibb to Present New Data on 20 Types of Cancer from Across its Oncology Portfolio at ASCO and EHA 2019 Business Wire |
| 02:15PM | Bristol-Myers Squibb: A Long Idea for Aggressive Traders Only TheStreet.com |
| 01:01AM | Biocartis Group NV: Idylla(TM) MSI Performance Study Selected for Publication at ASCO Conference GlobeNewswire |
| May-15-19 09:27AM | Pfizer's Bavencio+Inlyta Combo Gets FDA Nod for Kidney Cancer Zacks |
| May-14-19 06:11PM | Lawsuit accuses Gilead of propping up cost of lifesaving HIV treatments by blocking generic competition CNBC |
| 04:31PM | These Sleepy Stocks Have Done Nothing, But May Wake Up GuruFocus.com |
| 10:00AM | Zacks.com featured highlights include: BlackRock, Northrop, Progressive, Interpublic Group and Bristol-Myers Zacks |
| 07:15AM | Award-Winning Actor and Producer Sterling K. Brown Joins Bristol-Myers Squibb in Effort to Share Stories of What Its Like to Live with Cancer Today Business Wire |
| 06:59AM | Bristol-Myers Squibb to Take Part in the UBS Global Healthcare Conference Business Wire |
| May-13-19 01:03PM | Why Bristol-Myers Squibb's $19 Billion Debt Issuance to Buy Celgene Makes Sense GuruFocus.com |
| 08:50AM | Buy These 5 Stocks With Impressive Sales Growth Right Away Zacks |
| 08:45AM | Bristol-Myers (BMY) is an Incredible Growth Stock: 3 Reasons Why Zacks |
| May-11-19 02:51AM | AVEO Pharmaceuticals (AVEO) Q1 Earnings & Revenues Miss Mark Zacks |
| May-10-19 03:29PM | AVEO Pharmaceuticals (AVEO) Q1 Earnings & Revenues Miss Mark Zacks |
| 02:41PM | Endo (ENDP) Q1 Earnings & Revenues Beat Estimates Zacks |
| 08:23AM | Can Bristol-Myers Squibb Company's (NYSE:BMY) ROE Continue To Surpass The Industry Average? Simply Wall St. |
| May-09-19 02:33PM | Nektar (NKTR) Q1 Earnings & Revenues Beat, Decline Y/Y Zacks |
| 01:28PM | Why this former health care CEO thinks this Uber board member is crucial to its success Yahoo Finance Video |
| 10:21AM | Zacks.com featured highlights include: Exantas Capital, Lamb Weston, Bristol-Myers Squibb, Amedisys and Computer Programs and Systems Zacks |
| 10:07AM | Bristol-Myers Squibb's Opdivo Stumbles In Late-Stage Brain Cancer Study Benzinga |
| 09:15AM | Why Bristol-Myers Squibb (BMY) is a Top Dividend Stock for Your Portfolio Zacks |
| 07:39AM | Bristol-Myers' Opdivo fails late-stage brain cancer trial Reuters |
| 06:59AM | Bristol-Myers Squibb Announces Phase 3 CheckMate -498 Study Did Not Meet Primary Endpoint of Overall Survival with Opdivo (nivolumab) Plus Radiation in Patients with Newly Diagnosed MGMT-Unmethylated Glioblastoma Multiforme Business Wire |
| May-08-19 04:31PM | IBM Gets a Tepid Reception for Its $20 Billion Bond Sale Barrons.com |
| 04:00PM | Mallinckrodt (MNK) Beats on Q1 Earnings & Sales, Raises View Zacks |
| 02:45PM | Aerie (AERI) Q1 Earnings Beat, Rhopressa Misses Estimates Zacks |
| 12:06PM | Aduro (ADRO) Q1 Earnings and Revenues Fall Shy of Estimates Zacks |
| 09:56AM | Array BioPharma (ARRY) Q3 Earnings and Sales Beat Estimates Zacks |
| 09:46AM | Clovis (CLVS) Q1 Earnings Top Estimates, Rubraca Sales Strong Zacks |
| 09:33AM | Infinity (INFI) Earnings and Sales Miss Estimates in Q1 Zacks |
| 08:51AM | Prothena's (PRTA) Q1 Earnings Beat Estimates, Revenues Miss Zacks |
| 07:46AM | 5 ROE Stocks to Profit as Trade Woes Shake Equity Markets Zacks |
| 07:33AM | 5 Stocks With Upgraded Broker Ratings Worth Betting on Now Zacks |
| 07:00AM | Market Morning: Mylan Massacre, Futures Dither, Meatless McDonalds, Uber Drivers Bash Greed, Want More Money Market Exclusive |
| 06:59AM | Bristol-Myers Squibb Company Prices $19 Billion of Senior Unsecured Notes Business Wire |
| 06:42AM | Bet on Top Stocks With Rising P/E to Enjoy Solid Gains Zacks |
| 06:30AM | Should Investors Worry About Corporate Debt? It Depends on Who You Ask. Barrons.com |
| May-07-19 05:46PM | Bristol-Myers Borrows $19 Billion in Year's Biggest Bond Deal Bloomberg |
| 04:12PM | What Comes After 2019s Biggest Bond Deal? A Big Debt Diet Bloomberg |
| 01:54PM | Bristol-Myers Squibb Is Selling $19 Billion of Bonds to Buy Celgene Barrons.com |
| 09:35AM | What's in the Cards for Nektar (NKTR) This Earnings Season? Zacks |
| 08:58AM | Will Higher Expenses Dent Cronos' (CRON) Earnings in Q1? Zacks |
| 08:05AM | Bausch's (BHC) Q1 Earnings Beat Estimates, Revenues Miss Zacks |
| 02:59AM | Bristol-Myers Squibb in $19bn debt sale to fund Celgene deal Financial Times |
| May-05-19 12:29PM | Need to know: Max grounding costs mount, an Elysian remake and the story behind an Escala penthouse American City Business Journals |
| May-03-19 01:08PM | Bristol-Myers Acquisition of Celgene Is a Prescription for Success, One Analyst Says Barrons.com |
| 06:00AM | Seattle life sciences industry has strength in numbers despite uncertainty American City Business Journals |
| May-02-19 06:28PM | Cramer reviews the top activist stories of 2019: eBay, Dollar Tree, Bristol-Myers, and Bed Bath & Beyond CNBC |
| 12:08PM | Bristol-Myers Squibb Company -- Moody's assigns A2 to Bristol-Myers's sr. notes; under review for downgrade Moody's |
| 11:21AM | Exelixis (EXEL) Earnings & Revenues Beat Estimates in Q1 Zacks |
| 10:42AM | The Zacks Analyst Blog Highlights: FirstEnergy, Synchrony Financial, ExxonMobil, Morgan Stanley and Bristol-Myers Zacks |
| May-01-19 09:06PM | Bristol-Myers Squibb Company Announces Results of Early Participation in Exchange Offers and Consent Solicitations for Celgene Corporation Notes Business Wire |
| 06:00PM | The top 2 health care names to play for a catch-up: Technician CNBC Videos |
| 05:46PM | Bristol-Myers Squibb Company Announces Launch of Private Offering of Senior Unsecured Notes Business Wire |
| 02:56PM | Top Research Reports for ExxonMobil, Morgan Stanley & Bristol-Myers Zacks |
| Apr-30-19 07:00PM | Top Biotech Stocks for February 2019 Investopedia |
| 06:56PM | Puerto Rico board files flurry of lawsuits ahead of claim deadline Reuters |
| 03:18PM | Trump, Democratic leaders to meet on drug prices soon -White House Reuters |
| 10:53AM | The 10 Best Health Care Stocks to Buy for 2019 Kiplinger |
| Apr-29-19 03:19PM | Celgene's Final Earnings Report? Motley Fool |
| 01:08PM | 52-Week Company Lows GuruFocus.com |
| 11:29AM | 3 Stocks Peter Lynch Would Love Motley Fool |
| Apr-27-19 10:39PM | Stocks That Fell to 3-Year Lows in the Week of April 26 GuruFocus.com |
| 11:29AM | Biosimilar competition to AbbVies Humira is eroding profits, but company says it has confidence in pipeline MarketWatch |
| Apr-26-19 05:36PM | 2 Large Drug Manufacturers Release 1st-Quarter Results GuruFocus.com |
| 02:20PM | Edited Transcript of BMY earnings conference call or presentation 25-Apr-19 2:30pm GMT Thomson Reuters StreetEvents |
| 01:44PM | Celgene (CELG) Q1 Earnings Beat Estimates on Revlimid Sales Zacks |
| 08:45AM | 3 Reasons Why Growth Investors Shouldn't Overlook Bristol-Myers (BMY) Zacks |
| Apr-25-19 04:06PM | These Pharmas Beat First-Quarter Forecasts; But Biosimilars Rankled One Investor's Business Daily |
| 02:52PM | Bristol-Myers Q1 Earnings Beat, Sales Up on Strong Eliquis Zacks |
| 02:45PM | Bristol-Myers Squibb Co (BMY) Q1 2019 Earnings Call Transcript Motley Fool |
| 01:26PM | Bristol-Myers Squibb Earnings: BMY Stock Pops on Q1 Beat InvestorPlace |
| 01:03PM | Bristol-Myers Squibb Posts Solid Q1 Results With the Celgene Acquisition Looming Motley Fool |
| 10:08AM | Pfizer Stock Has Positive and Negative Catalysts Going Into Results InvestorPlace |
| 09:55AM | Bayer (BAYRY) Q1 Earnings Beat Estimates, Revenues Up Y/Y Zacks |
| 09:48AM | Bristol-Myers Tops Q1 Earnings Estimate After Winning Celgene Takeover Approval TheStreet.com |
| 09:42AM | Exelixis (EXEL) to Report Q1 Earnings: What's in Store? Zacks |
| 07:58AM | The Daily Biotech Pulse: Adverum Gets New CFO, Flexion's Osteoarthritis Trial, Bristol-Myers Earnings Benzinga |
| 07:55AM | Bristol-Myers: 1Q Earnings Snapshot Associated Press |
| 07:32AM | 3 Big Stock Charts for Thursday: Discovery, Norfolk Southern and Bristol-Myers Squibb InvestorPlace |
| 07:11AM | Bristol-Myers profit slightly tops Wall Street view on blood thinner sales Reuters |
| 07:00AM | Bristol-Myers profit slightly tops Wall Street view on blood thinner sales Reuters |
| 06:59AM | Bristol-Myers Squibb Reports First Quarter Financial Results Business Wire |
| 06:30AM | Bristol-Myers Squibb Reports Earnings Today. Heres What to Expect. Barrons.com |
| 05:33AM | Stocks Edge Lower as Growth Concerns Resurface, Offsetting Solid US Earnings TheStreet.com |
|
|
|
|
| Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis. It also provides Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for the treatment of patients with unresectable or metastatic melanoma; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; and Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B. In addition, the company offers Reyataz, a protease inhibitor for the treatment of human immunodeficiency virus (HIV) and Evotaz; Sustiva franchise, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV; and Daklinza NS5A replication complex inhibitor, Sunvepra NS3 protease inhibitor, and Beclabuvir NS5B inhibitor. It sells products to wholesalers, retail pharmacies, hospitals, government entities, and medical profession. It has collaboration agreements with Nektar Therapeutics; Janssen Pharmaceuticals, Inc.; Biocartis Group NV.; and FameWave Ltd. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Samuels Theodore R. II | Director | May 16 | Buy | 47.29 | 5,000 | 236,440 | 27,000 | May 20 04:36 PM | | Santiago Karen Murphy | Controller | May 16 | Sale | 47.56 | 3,065 | 145,771 | 3,066 | May 20 04:37 PM | | Caforio Giovanni | Chairman and CEO | May 05 | Option Exercise | 0.00 | 8,040 | 0 | 373,239 | May 06 04:40 PM | | Lynch Thomas J. Jr. | EVP & Chief Scientific Officer | Apr 03 | Option Exercise | 0.00 | 11,594 | 0 | 25,816 | Apr 05 04:32 PM | | Dubow Adam | Chief Compliance & Ethics Offi | Mar 10 | Option Exercise | 0.00 | 3,735 | 0 | 18,240 | Mar 13 07:41 AM | | Caforio Giovanni | Chairman and CEO | Mar 10 | Option Exercise | 0.00 | 173,419 | 0 | 422,683 | Mar 13 07:40 AM | | Bancroft Charles A | EVP & Chief Financial Officer | Mar 10 | Option Exercise | 0.00 | 62,255 | 0 | 411,547 | Mar 13 07:39 AM | | Biondi Paul | SVP, Head of Strategy & BD | Mar 10 | Option Exercise | 0.00 | 8,619 | 0 | 7,860 | Mar 13 07:39 AM | | von Autenried Paul | SVP, Enterp. Services & CIO | Mar 10 | Option Exercise | 0.00 | 19,925 | 0 | 141,077 | Mar 13 07:38 AM | | Schmukler Louis S | Pres., Global Mfg. & Supply | Mar 10 | Option Exercise | 0.00 | 26,568 | 0 | 63,652 | Mar 13 07:37 AM | | Lynch Thomas J. Jr. | EVP & Chief Scientific Officer | Mar 10 | Option Exercise | 0.00 | 5,864 | 0 | 21,343 | Mar 13 07:36 AM | | Santiago Karen Murphy | Controller | Mar 10 | Option Exercise | 0.00 | 3,825 | 0 | 6,850 | Mar 13 07:37 AM | | LEUNG SANDRA | EVP, General Counsel | Mar 10 | Option Exercise | 0.00 | 45,170 | 0 | 558,854 | Mar 13 07:35 AM | | JUDGE ANN POWELL | SVP, Global Human Resources | Mar 10 | Option Exercise | 0.00 | 25,577 | 0 | 81,508 | Mar 13 07:34 AM | | Elicker John E | SVP, Public Affairs & IR | Mar 10 | Option Exercise | 0.00 | 14,180 | 0 | 92,626 | Mar 13 07:42 AM | | BOERNER CHRISTOPHER S. | EVP, Chief Commercial Officer | Mar 10 | Option Exercise | 0.00 | 15,707 | 0 | 14,501 | Mar 13 07:41 AM | | Bancroft Charles A | EVP & Chief Financial Officer | Feb 28 | Option Exercise | 17.51 | 52,884 | 925,999 | 392,690 | Mar 04 04:42 PM | | LEUNG SANDRA | EVP, General Counsel | Feb 28 | Option Exercise | 17.51 | 169,893 | 2,974,826 | 634,478 | Mar 04 04:42 PM | | BOERNER CHRISTOPHER S. | EVP, Chief Commercial Officer | Feb 02 | Option Exercise | 0.00 | 4,465 | 0 | 4,465 | Feb 05 04:53 PM | | Bancroft Charles A | EVP & Chief Financial Officer | Dec 02 | Option Exercise | 0.00 | 6,401 | 0 | 206,117 | Dec 04 04:31 PM | | Biondi Paul | SVP, Head of Strategy & BD | Oct 02 | Option Exercise | 0.00 | 592 | 0 | 592 | Oct 04 04:56 PM | | Dubow Adam | Chief Compliance & Ethics Offi | Sep 03 | Option Exercise | 0.00 | 797 | 0 | 15,495 | Sep 05 04:49 PM | | Santiago Karen Murphy | Controller | Sep 01 | Option Exercise | 0.00 | 641 | 0 | 4,057 | Sep 05 04:49 PM | | Gordon Murdo | EVP, Chief Commercial Officer | Aug 01 | Option Exercise | 0.00 | 1,510 | 0 | 50,168 | Aug 03 05:05 PM | | Biondi Paul | SVP, Head of Strategy & BD | Jul 01 | Option Exercise | 0.00 | 1,461 | 0 | 1,461 | Jul 03 09:24 PM |
|
|
|
|
|
|
